News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pierre Fabre's Bladder Cancer Drug, Javlor too Costly for National Health Service, National Institute for Clinical Excellence (NICE) Says


11/23/2010 7:40:42 AM

Pharma Times -- t looks like patients with advanced cancer of the urothelial tract will not be getting access to Pierre-Fabre’s Javlor on the National Health Service, after the drug was deemed too expensive by NICE.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES